Search

Displaying results 2231 - 2240 of 7498 in total
  1. Drug

    Glatiramer

    go.drugbank.com/drugs/DB05259
    ApprovedInvestigational

    [A248880] It was approved by the FDA in 1996, and a generic version became available in 2017. … Glatiramer acetate exhibits several immunomodulatory effects and reduces the relapse rate of relapsing-remitting multiple sclerosis (RRMS) by 30%.

  2. Drug

    Birch bark extract

    go.drugbank.com/drugs/DB16536
    ApprovedInvestigational

    [L42390] Filsuvez was subsequently approved for the same indication by the US FDA in December 2023. … [L50031] The EMA marketing authorization for Episalvan[L42370] was withdrawn by the manufacturer in 2022.

  3. Drug

    Cupric oxide

    go.drugbank.com/drugs/DB11134
    Approved

    Cupric oxide poses potential health and environmental concern due to toxic and mutagenic particles generating reactive oxygen species [A32656].

  4. Drug

    Baricitinib

    go.drugbank.com/drugs/DB11817
    ApprovedInvestigational

    [L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018. … By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses.

  5. Drug

    Mangafodipir

    go.drugbank.com/drugs/DB06796
    ApprovedInvestigationalWithdrawn

    Teslascan has been removed from the Drug Product List by FDA in 2003, and withdrawn from the European market in 2012. … Enhanced contrast by mangafodipir improves visualization and detection of lesions of the liver formed from metastatic disease or hepatocellular carcinomas.

  6. Drug

    Inositol nicotinate

    go.drugbank.com/drugs/DB08949
    ApprovedWithdrawn

    It is associated with reduced flushing compared to other vasodilators by being broken down into the metabolites and inositol at a slower rate. … Inositol nicotinate, also known as Inositol hexaniacinate/hexanicotinate or "no-flush niacin", is a niacin ester and vasodilator.

  7. Drug

    Somatrogon

    go.drugbank.com/drugs/DB14960
    ApprovedInvestigational

    growth hormone caused by growth hormone deficiency, marking Canada as the first country to approve this drug. … It is a chimeric product generated by fusing three copies of the C-terminal peptide (CTP), or 28 carboxy-terminal residues, from the beta chain of human chorionic gonadotropin (hCG) to the N-terminus and

  8. Drug

    Sutilain

    go.drugbank.com/drugs/DB09379
    ApprovedWithdrawn

    [T169] Sutilain was developed by Abbott and FDA approved on June 12, 1969. It is currently discontinued.[L2368] … It is able to dissolve the intercellular matrix which helps with desquamation.

  9. Drug

    Betibeglogene autotemcel

    go.drugbank.com/drugs/DB16900
    ApprovedInvestigational

    [L42940] β-thalassemia is a condition caused by mutations in the β-globin gene (HBB) that leads to a significant decrease in the production of β-globin. … The use of betibeglogene autotemcel is more effective in patients with β-thalassemia with residual β-globin synthesis (non-β<sup>0</sup>/β<sup>0</sup> genotype) compared to those with no detectable β-globin

  10. Drug

    Aminohippuric acid

    go.drugbank.com/drugs/DB00345
    ApprovedInvestigationalWithdrawn

    Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity. [PubChem]

    Synonyms: N-(p-Aminobenzoyl)glycine, N-(para-aminobenzoyl)glycine